USE IN PREGNANCY
When pregnancy is detected, discontinue Azor as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus [see Warning and Precautions].
USE IN PREGNANCY
AZOR™ is a combination of the calcium channel receptor blocker (CCB) amlodipine besylate and the angiotensin II receptor blocker (ARB) olmesartan medoxomil.
AZOR™ is indicated for the treatment of hypertension, alone or with other antihypertensive agents.
This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION).
Media Articles Related to Azor (Amlodipine / Olmesartan)
Reconstructive surgery may be aided by 'squid sucker ring teeth' material
Source: Cosmetic Medicine / Plastic Surgery News From Medical News Today [2014.07.04]
Squid tentacles are loaded with hundreds of suction cups, or suckers, and each sucker has a ring of razor-sharp "teeth" that help these mighty predators latch onto and take down prey.
Calorie restriction improves sleep apnea, hypertension in obese people
Source: Hypertension News From Medical News Today [2014.09.12]
Restricting calories may improve obstructive sleep apnea and reduce high blood pressure in obese adults, according to a study presented at the American Heart Association's High Blood Pressure...
Hypertension up to Six Times More Likely in Obese vs Slim Youth
Source: theheart.org | Medscape Cardiology Headlines [2014.09.10]
Overweight and obese boys and girls were much more likely to have hypertension than normal-weight children in a new study; thus, weight loss should be encouraged to reduce later CVD risk.
Hypertension is a nearly 6 fold risk factor in obese youths
Source: Hypertension News From Medical News Today [2014.09.03]
Obese youths have a nearly six fold risk of hypertension, according to research in more than 22 000 young people from the PEP Family Heart Study presented at ESC Congress by Professor Peter Schwandt...
Stroke risk increased by resistant hypertension: 35 percent in women and 20 percent in elderly Taiwanese
Source: Hypertension News From Medical News Today [2014.09.03]
Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research presented at ESC Congress by Dr Kuo-Yang Wang from Taiwan.
Published Studies Related to Azor (Amlodipine / Olmesartan)
A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/- hydrochlorothiazide. [2011.06]
In the prospective, open-label, titrate-to-goal Blood Pressure Control in All Subgroups With Hypertension (BP-CRUSH) study, 999 patients with hypertension uncontrolled on monotherapy (mean age, 55.6 +/- 11.4 years; baseline blood pressure [BP], 153.7 +/- 9.2/91.9 +/- 8.6 mm Hg) were switched to fixed-dose amlodipine/olmesartan medoxomil (AML/OM) 5/20 mg...
Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies. [2009.01]
BACKGROUND: Most patients with hypertension require more than one drug to attain recommended blood pressure (BP) targets. Initiating therapy with two agents is recommended for patients at high risk of a cardiovascular event or with a BP > 20/10 mmHg above goal. Combination therapy is effective when comprised of agents with complementary mechanisms of action, such as calcium channel blockers (CCBs) and angiotensin II-receptor blockers (ARBs). Two fixed-dose CCB/ARB combinations are approved in the US: amlodipine/valsartan (AML/VAL) and amlodipine/olmesartan medoxomil (AML/OM). OBJECTIVES: To review and describe the efficacy of AML/VAL and AML/OM combinations by discussing similarly designed clinical trials... CONCLUSIONS: This review of published factorial-design studies showed that the maximal marketed doses of an amlodipine/olmesartan medoxomil combination (10/40 mg) and an amlodipine/valsartan combination (10/320 mg) produced large reductions in BP from baseline. Limitations of this review include the small number of studies analyzed and the inherent heterogeneity between patient populations. Further research is warranted to directly compare the efficacy of these combinations in a randomized, controlled trial, or additional published clinical trials are required to provide larger data sets for robust meta-analyses and to overcome heterogeneity observed within these studies.
Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. [2011.06]
A subgroup analysis of a prospective, open-label, single-arm titration study in patients with hypertension and type 2 diabetes or obesity is reported. The primary end point was the change from baseline in mean 24-hour ambulatory systolic blood pressure (BP) after 12 weeks... The SeBP goal of < 130/80 mm Hg was achieved by 26.1% of patients with diabetes and <140/90 mm Hg was achieved by 78.1% of obese patients.
Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. [2011.05.01]
The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension. After a 2- to 3-week placebo run-in period, 207 patients received amlodipine 5 mg and were uptitrated to amlodipine/OM 5/20, 5/40, and 10/40 mg and then amlodipine/OM 10/40 mg plus hydrochlorothiazide 12.5 and 25 mg in a step-wise manner at 3-week intervals if the seated blood pressure (BP) remained >/=120/70 mm Hg...
A titrate-to-goal study of switching patients uncontrolled on antihypertensive
monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil Â±
In the prospective, open-label, titrate-to-goal Blood Pressure Control in All
Subgroups With Hypertension (BP-CRUSH) study, 999 patients with hypertension
uncontrolled on monotherapy (mean age, 55.6 Â± 11.4 years; baseline blood pressure
[BP], 153.7 Â± 9.2/91.9 Â± 8.6 mm Hg) were switched to fixed-dose
amlodipine/olmesartan medoxomil (AML/OM) 5/20 mg...
Clinical Trials Related to Azor (Amlodipine / Olmesartan)
A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure [Recruiting]
The initial 12 week portion of this 20 week study will examine the ability of a combination
of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high
blood pressure who have not had sufficient blood pressure reduction using one
anti-hypertension drug (monotherapy). The final 8 weeks of this 20 week study will examine
the ability of a combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide to
lower blood pressure in the same patient population. All three medications being tested have
been approved by the FDA for the treatment of high blood pressure, but only amlodipine and
olmesartan are currently approved for use in combination form.
Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients [Recruiting]
Parallel-Group Comparison of Olmesartan, Amlodipine and Hydrochlorothiazide in Hypertension [Recruiting]
This study is to determine the change in blood pressure from the administration of
Olmesartan/Amlodipine/Hydrochlorothiazide triple combinations compared to dual combinations
Reports of Suspected Azor (Amlodipine / Olmesartan) Side Effects
Oedema Peripheral (4),
Abdominal Discomfort (3),
Blood Pressure Increased (3),
Weight Decreased (2), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Azor has an overall score of 8. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Azor review by 23 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || anxiety attacks|
|Dosage & duration:|| || 0.5g/day (dosage frequency: once a day or when needed) for the period of for a total of eight years now|
|Other conditions:|| || chronic back pain|
|Other drugs taken:|| || nothing |
|Benefits:|| || Can get a good nights rest and anxiety attacks are supressed. I have been able to lead a normal life and be successfull. I am doing my doctoral now in medical research and belief without Azor it would not be possible. I remember what my life was before Azor and am relieved to know it is behind me. I have been on it for years now, the benefits outweighs the disadvantages- I know Im addicted. Azor was and still is prescribed to me by my psychiatrist.|
|Side effects:|| || Some lethargic tendencies and drowsiness at times when taken for anxiety attack. Also, I am addicted to it. I can not sleep witout Azor.|
|Comments:|| || I take one tablet (0.5g) Azor whenever I have a anxiety attack or struggle to sleep.
I was attacked a few years back, and still have panic attacks on occasion and struggle to sleep considerably. In addition, I have nightmares. However, when I take the azor, I calm down. Furthermore,I did try sleeping medication, however,I was always tired and struggled to wake up. When I take azor, I can sleep without the whooziness the following morning. |
Page last updated: 2014-09-12